Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio?

After withdrawing ALS drug Relyvrio from the U.S. and Canadian markets and laying off 70% of its workforce, the Cambridge, Mass.–based biopharma got a much-needed win in Wolfram syndrome.